A randomized, open, controlled clinical trial was designed to evaluate the efficacy, tolerance, and safety of sodium stibogluconate plus allopurinol and sodium stibogluconate alone as treatment of patients with mucocutaneous leishmaniasis. In phase 1 of the study, all 22 patients with severe disease had improvement of their lesions, but only two had clinical cure (both of these patients received sodium stibogluconate alone). In phase 2, which included 59 patients with moderate disease, the cure rate among sodium stibogluconate recipients was 75% (21 of 28) compared with 63.6% (14 of 22) among the sodium stibogluconate plus allopurinol recipients. The rates of clinical adverse events were similar among both groups. Thrombocytopenia was more frequent in the sodium stibogluconate plus allopurinol recipients, but the difference was not statistically significant. Eight patients (two sodium stibogluconate recipients and six sodium stibogluconate plus allopurinol recipients) withdrew from the study because of severe thrombocytopenia. In this study, the addition of allopurinol to sodium stibogluconate provided no clinical benefit as treatment of mucocutaneous leishmaniasis.
Infection of the oronasal membranes with Leishmania paraweight for a minimum of 4 weeks have been recommended [4] . The efficacy of these agents varies according to the severity sites (mucosal leishmaniasis) is a devastating late consequence of the disease [5, 6] . When the disease is restricted to the nose, of cutaneous leishmaniasis. Progression of disease in the nose the cure rate is 83%, and it falls to 7% when the larynx and frequently results in septal perforation or collapse of the anteespecially the vocal cords are involved. The problem in cases rior nares or the whole nasal pyramid. Involvement of the of mucocutaneous leishmaniasis (MCL) is the treatment of palate, uvula, pharynx, and tonsils can lead to loss of the uvula, patients with severe and moderate disease. Other drugs have adhesion (''gluing'') of the soft palate to the posterior orophabeen used (including amphotericin B, metronidazole, ketoconaryngeal wall, and narrowing of the oral canal due to tonsillar zole, and rifampin), but more toxic effects and/or lower effecfibrosis. Laryngeal disease leads to a hoarse voice and potentiveness was observed with these agents than with Sb5/ [7] . tially to suffocation when the trachea and bronchi are severely Therefore, there is a need to continue searching for new treatinvolved. Very serious esthetic and functional sequelae occur ments of MCL. in the worst cases [1, 2] . Although there is qualitatively greater Purine metabolism in Leishmania differs from that in hulymphocyte blastogenesis, IFN-g production, and delayed hymans. In Leishmania, certain purine analogues are aminated to persensitivity in patients with mucosal leishmaniasis than in analogues of adenosine nucleotides and incorporated into RNA. those with cutaneous leishmaniasis, only two cases of selfWhen this occurs, protein synthesis is halted. To exploit this healed mucosal disease have been reported [1] . difference in metabolism, purine analogues have been sugPentavalent antimonial agents are still the drugs of choice gested as treatment of leishmaniasis [8] . Pyrazolopyrimidines for the treatment of mucosal leishmaniasis [3, 4] . Single daily have received the most attention as potential therapeutic agents, doses of pentavalent antimony (Sb5/) at 20 mg/kg of body and allopurinol has served as the prototype. There is evidence that allopurinol can inhibit the growth of Leishmania in vitro and in tissue culture. Allopurinol and sodium stibogluconate (a meglumine antimoniate alone to 74% with the combination of (Geneva) and the Ethical Committee of Universidad Peruana Cayetano Heredia (Lima, Peru). meglumine antimoniate and allopurinol [11] . In a recent study in Iran, the cure rate associated with this therapeutic combination for drug-resistant disease was 96% (24 of 25 cases) [12] .
This study was designed to assess the efficacy, safety, and systemic disease. The use of any other antileishmanial drugs years of age were eligible for study enrollment if they had a was not allowed. Side effects were managed according to documented history of MCL with proven presence of parasites guidelines prepared before the start of the study. by culture and/or PCR analysis [13] and gave written informed
The patients were admitted to the Hospital Regional del consent. The exclusion criteria were clinically similar diseases Cusco (Cusco, Peru) during the administration of therapy. After (such as tuberculosis, leprosy, lymphoma, and paracoccidioidoenrollment and baseline laboratory evaluation, the patients were mycosis), serious concomitant diseases, pregnancy, known or assessed on the basis of clinical and laboratory parameters suspected allergy to Sb5/ or allopurinol, and use of Sb5/, until the end of the treatment. The nasal, oral, pharyngeal, and allopurinol, amphotericin B, or ketoconazole in the last 6 laryngeal membranes were reexamined at the end of therapy months before the study. Subjects were recruited from two and every 3 months thereafter for 12 months. Samples of the patient associations and two medical centers in Cusco, Peru. mucosal lesions were obtained for repeated cultures at the end Approval from the ethics committee was obtained before startof treatment or when it was clinically indicated (always with ing the study. the patient's agreement). When patients did not attend their follow-up, our field workers visited the patients at their homes.
Study Design
The study was designed as a randomized, open (not blinded),
Definitions
comparative clinical trial. At enrollment time, the patients were randomized according to a permuted-blocks scheme with a Severity of MCL was defined combining the criteria of mublock size of 10 patients. The study was divided into two phases cosal lesion extension and severity of symptoms as follows: because the rate of cure of MCL varies with the severity of moderate, involvement of more than two mucous membranes the disease. When the study began in 1989, our aim was to with mild or no respiratory distress; and severe, moderate disenroll patients with severe and moderate MCL. According to ease plus severe respiratory distress. our previous experience, the cure rate associated with therapy
The criterion of mucosal lesion extension depends on the with pentavalent antimonial agents alone for severe MCL is number of mucous areas with disease (anatomically), and the õ10% [6]. We calculated a sample size of 44 patients to detect criterion of severity of symptoms depends on the physiological a difference of efficacy of at least 40% (we expected a cure changes produced by the disease. Severity of symptoms was rate of 50% to be associated with sodium stibogluconate plus considered as follows: mild, those symptoms confined to the allopurinol). Because of the high failure rate associated with nose; moderate, odynophagia, dysphonia, and/or mild respiraboth treatment schemes for the first 22 patients (all of them tory distress; and severe, odynophagia, dysphonia, and severe had severe disease), it became unacceptable to include more respiratory distress. patients with severe disease.
In phase 2, we admitted only patients with moderate disease. The sample size was calculated as 59 patients to detect a differOutcomes During Follow-up ence of efficacy of 40% between both regimens (we expected a cure rate of 40% to be associated with sodium stibogluconate
Outcomes during the 12-month follow-up period were defined as follows: primary failure, lack of improvement of the alone and a cure rate of 80% to be associated with sodium stibogluconate plus allopurinol), with an a error of 0.05 and a lesions during treatment; improvement, reduction in the size of the lesions; and relapse, enlargement of the area of the lesion b error of 0.80 (considering losses of 5%). All changes in the study design were made and formalized by the I-CHEM Steerwith an increase of the inflammatory tissue at the original site or appearance of new lesions after improvement or complete 
Results

Patient Characteristics
Final outcomes were defined as follows: clinical cure, complete clinical healing of the lesions with disappearance of A total of 81 patients met the eligibility criteria and were enrolled in the study from January 1989 to February 1992. edema, induration, or other inflammatory signs (complete scarring or epithelialization) and negative culture or PCR tests for Twenty-two patients in phase 1 and 59 in phase 2 were randomized to either group A or group B. Montenegro tests for all at least the 12-month follow-up period; and clinical failure, both primary treatment failure and relapse apart from the results patients were positive, and 18 (85.7%) of 21 patients in phase 1 and 59 (100%) of the patients in phase 2 had positive parasitoof culture or PCR analysis. The possibility of a patient's condition improving at the 12-month follow-up but not achieving logical tests (culture, smear, and/or PCR tests) before starting therapy. All of 35 strains studied by the PCR method belonged either clinical cure or failure was not observed in practice.
to the Leishmania braziliensis complex. In addition, cultures of specimens from 20 patients were characterized by isoenzyme analysis as L. braziliensis following the methods described by
Adverse Events
Arana et al. [14] . Both groups are compared in tables 1 and 2. The groups Before the administration of the next dose of therapy, the were comparable in terms of epidemiological, demographic, patients were asked daily about the presence of any new sympand clinical characteristics in both phases of the study. We did tom. The adverse events were recorded during a structured not find differences in age, sex, weight, length of residence in interview with a checklist. Laboratory tests were performed at the place of transmission, economic activity, duration of the baseline and every week during the treatment period to evaluate disease (cutaneous plus mucosal), duration of mucosal disease, the toxicity of the drugs. Hematologic tests determined hemoprevious treatment, extension of the mucous lesions, or sympglobin level, hematocrit, WBC count with differential blood tomatology. All patients were admitted to the hospital during cell count, and platelet count. Serum biochemistry tests meatheir first mucosal episode. sured aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, alkaline phosphatase level, bilirubin
Response to Therapy level, and creatinine level. Urinalysis determined pH, glucose level, and protein level; the urinary sediment was examined to Two of 22 patients in phase 1 withdrew from the study, detect leukocytes, erythrocytes, casts, and crystals.
one because of severe thrombocytopenia and one because of Anemia was defined as a decrease in the basal hemoglobin intercurrent disease (typhoid fever). Nine of the 59 patients in level or a hematocrit of §10%. Leukopenia was defined as a phase 2 withdrew from the study because of toxicity related WBC count of õ4,000 cells/mm 3 . Thrombocytopenia was deto the treatment. Therefore, 20 patients in phase 1 and 50 in fined as a platelet count of õ140,000/mm 3 , and severe thromphase 2 were included in the analysis of efficacy. Ninety perbocytopenia was defined as a platelet count of õ70,000/mm 3 .
cent of patients adhered to follow-up procedures, but all were Hepatic abnormality was reported when there was an increase evaluated at the 12-month follow-up (table 3) . of ú20% higher than the pretherapy values of alkaline phosIn phase 1, every patient's lesions improved by the end of phatase, bilirubin, AST, or ALT. Renal abnormality was retherapy, but only two of them had clinical cure as a final ported if the serum creatinine level was at least 0.3 mg/dL outcome (both belonged to group A and had no involvement higher than the baseline value.
of the vocal cords Severe adverse events caused the withdrawal of one patient (21%) of 81 patients. The rate of anemia and leukopenia was similar among both groups, but the rate of thrombocytopenia (9.1%) from group A and one (9.1%) from group B in phase 1. In phase 2, two patients (6.7%) withdrew from group A, was higher among group B (not statistically significant). The hematologic toxic effect was dose dependent, with a median and seven (24.1%) withdrew from group B (Fisher's exact one-tailed test, P Å .065). The more frequent symptoms were of 18 days of treatment (range, 5 -28 days) before the effect was detected. Seven of eight patients who developed severe headache (81.5% of patients), arthralgia (75.3%), myalgia (67.9%), chills (42%), fever (39.5%), abdominal pain (33.3%), thrombocytopenia (platelet count, õ70,000/mm 3 ) had signs of mucous bleeding such as epistaxis, bleeding of the gums, or and anorexia (25.9%). Three patients developed ophthalmic herpes zoster (two in group B and one in group A) by the end petechiae. One patient developed melena, ecchymosis, and moderate epistaxis. of treatment (table 4). They were treated with acyclovir, but one of them developed partial blindness as a sequela.
Hepatic abnormality was manifested mainly as an increase in the AST or ALT level, usually less than two times the The most frequent laboratory adverse event was hematologic abnormality (table 5). We observed both anemia and leukopebaseline value. One patient in group B presented with hepatitis (AST and ALT levels rose between five and six times the nia in 22 (27.2%) of 81 patients and thrombocytopenia in 17 (100) 50 (100) ment, all eight patients had a sustained increase in their platelet counts, which reached normal values in 7 to 20 days. In group B, one patient developed severe bradycardia (heart rate of õ40 detected on day 10 of treatment) and recovered 14 days after baseline value, and the serum bilirubin level increased three the treatment was stopped. For two additional patients in group times). The rates of hepatic adverse events was similar among B, the treatment was stopped, because of hepatic abnormality both groups (table 5) . No significant changes in serum creatiin one and because of a new illness (typhoid fever) in one. nine levels were found.
In phase 2, the rate of serious adverse events, excluding the Minor and transient electrocardiographic abnormalities were patient who developed concomitant illness, was higher among detected during treatment of 89% of the patients, and no differgroup B (27.6% [eight of 29]; 95% CI, 0.6% -22.4%) than ence was detected between groups. The most common findings among group A (6.7% [two of 30]; 95% CI, 5.7% -36%), but were nonspecific ST segment and T wave changes and T wave the difference was not statistically significant (Fisher's exact inversion.
two-tailed test, P Å .254). All patients with severe reactions Eleven patients (13.6%) withdrew from the study because were hospitalized as inpatients until recovery. of serious adverse effects. Eight patients withdrew because of severe thrombocytopenia (platelet count, õ70,000/mm 3 ), two from group A and six from group B. After stopping the treatDiscussion
Since a synergistic action of allopurinol and antimonial com- The lack of benefit of the combination of Sb5/ plus allopurinol MCL by using a bronchoscope. In 18 patients, the trachea was involved, and in some patients, the disease also affected the groups did not reach statistical significance, but the confidence interval suggests that it was due to the small sample sizes bronchi. These findings could explain why patients with severe MCL develop severe respiratory distress. On the basis of results providing too little power to the trial.
There with severe disease or relapse [7, 22] . A randomized clinical trial comparing 28 days vs. 40 days of treatment for MCL was tried as treatment of six patients with mucosal leishmaniasis in an uncontrolled study in Brazil, but only two of the patients failed to show a benefit of prolonged therapy (63% cure rate among each group) [25] . were cured after 45-68 days of therapy [16] .
The literature on therapy for MCL is confusing because Obviously, monotherapy with pentavalent antimonial agents is not an ideal treatment for patients with severe and moderate apparently contradictory statements abound [7] . Pentavalent antimonial agents have been reported as ineffective [17] , as disease because of the high chance of treatment failure. Therefore, patients with severe and moderate MCL are candidates weakly effective [18] , and as frequently successful [19 -23] . Large differences in cure rates have been reported (30% to for testing new drugs or alternative treatments, such as drug combinations. Unfortunately, our results showed that adding 63%) by a single group of investigators studying therapy for MCL in Peruvian patients in the same locality (Cusco, Peru) allopurinol to antimony therapy provided no benefit for patients with severe or moderate MCL. [24, 25] .
Bryceson [7] stated that ''important limitations in published The main concern in this study was the high withdrawal rate (9.1% in phase 1 and 15% in phase 2) among both treatment reports on leishmaniasis therapy have been identified (inadequate designs, unclear diagnostic criteria, unclear definition of groups. All withdrawals but one were because of toxic effects of drugs. Most withdrawals were because of hematologic toxic evaluated outcomes, different dosages of the drug and duration of treatment, etc).'' We agree with these comments and believe effects, thus suggesting temporary bone marrow depression (temporary anemia, leukopenia, and/or thrombocytopenia). that we have shown that the severity of the disease is the main explanation for the differences in the reported rates of cure of Only one patient developed conspicuous bleeding signs (melena, epistaxis, and ecchymosis), but as a precaution, treatment MCL. Our group [5] reported different rates of cure in 50 cases of MCL and showed that the rates varied according to the was interrupted when platelet counts were õ70,000/mm 3 . The high rate of thrombocytopenia in our study and its resoseverity of the disease, which was estimated by using a score based on symptoms and signs. Later, in a case-control study lution after stopping treatment suggest that thrombocytopenia could be drug related. No statistical difference in frequency of and by use of multivariate analysis [6], we confirmed the influence of the severity of disease on the cure rate by studying 81 thrombocytopenia was found between both treatment groups, but the rate among group B (27.5%) was approximately twice patients with MCL on the basis of anatomic and functional criteria. The rates of chance of cure in patients with severe that among group A (14.6%); however, the difference was not statistically significant. In addition, withdrawals because MCL (involving four or more mucous membranes, including larynx and vocal cords), moderate MCL (involving the nasal of thrombocytopenia were more frequent in group B. The sample size was not large enough to detect the difference, but plus oral cavity [palate, pharynx, tonsils, and/or uvula and epiglottis]), and mild MCL (limited to nose membranes with the findings suggest that the association of allopurinol with pentavalent antimonial agents might have increased the rate or without septal perforation) were 7.1% (95% CI, 0 -34.6%), 40.9% (95% CI, 20.5% -63.8%), and 83.3% (95% CI, 60.9% -and severity of thrombocytopenia in the patients enrolled in our study. 91.2%), respectively.
Franke et al.
[24] reported different cure rates (10% vs. 75%, Recently, Hepburn [28] described severe thrombocytopenia related to sodium stibogluconate in a patient treated with 20 respectively) in cases of mild MCL (limited to nose) and severe MCL (involving the oral cavity as well as the nose). In a mg of antimony/(kgrd). However, this is not the first report of a hematologic toxic effect of this drug. Giraud et al.
[29] second study [25] , the cure rate was 63%, although the disease involved the oral cavity (severe disease according to Franke et reported two cases of hemorrhage related to sodium stibogluconate, and Franke et al. reported hematologic toxic effects in al.) in all patients. Limitations in the classification of the severity could explain the apparently contradictory results of those two studies, 11% of cases [24] and 7.5% of cases [25] . Therapy with sodium stibogluconate was discontinued for the patients reports. We consider that the main marker of severity in muco-/ 9c37$$se53 08-19-97 13:37:01 cida UC: CID in the latter two studies because of decreased platelet counts. In groups, the small sample size in this study provides little power to detect significant differences. addition, there are several reports of hematologic toxic effects (usually mild leukopenia and/or anemia) during therapy with
We believe that larger test groups of patients would perhaps uncover marginal differences, but these results would be not sodium stibogluconate for American diffuse cutaneous leishmaniasis [23, 30, 31] . clinically significant. We conclude that the combination of sodium stibogluconate and allopurinol does not provide benefit In our study, eight (9.9%) of 81 patients developed severe thrombocytopenia, and 23 (28.4%) of 81 patients had some for patients with severe and moderate MCL. The high morbidity rate, the high cost of treatment, and the low rate of cure, espeevidence of hematologic toxic effects. None of these patients but one, who developed typhoid fever, had any concomitant cially among patients with severe disease, demand that the search for alternative regimens to pentavalent antimonial agents systemic disease before or during Sb5/ therapy. Clinically, none of the patients was malnourished. We could not find alone continues. differences in terms of weight, age, or other clinical and demographic characteristics between patients with and without hematologic abnormalities.
